Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL343 in ALS
NCT05006352Phase 1Completed
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of DNL343 in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by Denali Therapeutics Inc. Primary endpoint: Incidence of treatment-emergent adverse events at 28 Days. Started Aug 2021; status: completed.
02
Drugs
DNL343
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05006352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006352.